Biotech M&A bare­ly show­ing sign of a pulse so far in 2017

With Pfiz­er wait­ing on fed­er­al tax re­form, a slew of phar­ma gi­ants shak­ing their heads over biotech val­u­a­tions and a few big play­ers stick­ing to the side­lines with­out any clear ex­pla­na­tion why, you al­ready knew that biotech M&A was down. In a new as­sess­ment of the takeover scene, Bloomberg came up with this snap­shot on glob­al M&A to date. It’s worth not­ing, though, that these an­nu­al sums can shift mas­sive­ly overnight, with one or two big deals mak­ing all the dif­fer­ence. The year isn’t over yet, but this graph tells you a lot about what the M&A scene has looked like so far. And while there’s lots of sup­port for tax re­form, there’s ab­solute­ly no sign that the pres­i­dent and Con­gress can agree on much of any­thing these days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER